One of the main problems with the treatment of metastatic prostate cancer is that, despite an
initial positive response, the majority of patients develop resistance and progress. In …

BACKGROUND Docetaxel is one of the primary drugs used for treating castration resistant
prostate cancer (CRPC). Unfortunately, over time patients invariably develop resistance to …

The majority of patients with prostate cancer treated with docetaxel develop resistance to it.
To better understand the mechanism behind the acquisition of resistance, we conducted …

Castration-resistant prostate cancer (CRPC) is a common form of prostate cancer in which
docetaxel-based chemotherapy is used as the first line. The present study is devoted to the …

Drug development for castration resistant prostate cancer (CRPC) is challenging, since this
cancer is still associated with high mortality and limited therapeutic options. In 2004 …

Docetaxel-based chemotherapy is the standard first-line therapy in metastatic castration-
resistant prostate cancer (CRPC). However, most patients eventually develop resistance to …

BACKGROUND Docetaxel‐resistance limits successful treatment of castration resistant
prostate cancer. We previously demonstrated that extracellular vesicles (exosomes) may …

Background: Biomarkers of therapeutic response and prognosis are needed to assist in the
sequencing of treatments for metastatic castration-resistant prostate cancer (CRPC) …

Docetaxel chemotherapy improves symptoms and survival in men with metastatic hormone-
refractory prostate cancer (HRPC). However,∼ 50% of patients do not respond to Docetaxel …

Simple Summary Therapeutic options for the treatment of men with metastatic castration-
resistant prostate cancer are limited. Docetaxel—a taxane-based chemotherapeutic agent …